Adaptive Announces Launch of Epic Integration for clonoSEQ®
This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care.
- This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care.
- clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT).
- Integration with Epic EHR provides convenient access to clonoSEQ MRD results along with discrete data directly in patient records, enabling faster, more efficient decision-making for oncologists and equipping patients with real-time insights into their disease status.
- Practices that wish to access clonoSEQ MRD testing directly via Epic should contact their Adaptive account representative or Adaptive’s Account Operations team at [email protected].